Renaissance Technologies (RenTech)'s LAB Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 992,058 shares of Standard BioTools Inc. (LAB) worth $816,166, representing 0.00% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 43 quarters.
Based on 13F filings since 2013, Renaissance Technologies (RenTech) has maintained a long-term strategic position in LAB, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2026, adding 992,058 shares. Largest reduction occurred in Q4 2020, reducing 1.46 M shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Standard BioTools (LAB) Holding Value Over Time
Track share changes against reported price movement
Quarterly Standard BioTools (LAB) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +992,058 | New Buy | 992,058 | $0.82 |
| Q4 2024 | -201,000 | Sold Out | 0 | $0.00 |
| Q3 2024 | -803,558 | Reduce 79.99% | 201,000 | $1.93 |
| Q2 2024 | -249,300 | Reduce 19.88% | 1 M | $1.77 |
| Q1 2024 | +214,258 | Add 20.61% | 1.25 M | $2.71 |
| Q4 2023 | +426,200 | Add 69.48% | 1.04 M | $2.21 |
| Q3 2023 | -11,909 | Reduce 1.90% | 613,400 | $2.90 |
| Q2 2023 | +289,009 | Add 85.94% | 625,309 | $0.00 |
| Q1 2023 | +36,200 | Add 12.06% | 336,300 | $0.00 |
| Q4 2022 | -44,000 | Reduce 12.79% | 300,100 | $0.00 |
| Q3 2022 | +112,200 | Add 48.38% | 344,100 | $1.10 |
| Q2 2022 | +114,400 | Add 97.36% | 231,900 | $1.60 |
| Q1 2022 | +100,000 | Add 571.43% | 117,500 | $3.59 |
| Q4 2021 | +17,500 | New Buy | 17,500 | $3.94 |
| Q1 2021 | -745,300 | Sold Out | 0 | $0.00 |
| Q4 2020 | -1.46 M | Reduce 66.25% | 745,300 | $6.00 |
| Q3 2020 | -1.16 M | Reduce 34.40% | 2.21 M | $7.43 |
| Q2 2020 | +178,818 | Add 5.61% | 3.37 M | $4.01 |
| Q1 2020 | +399,082 | Add 14.31% | 3.19 M | $2.54 |
| Q4 2019 | +42,740 | Add 1.56% | 2.79 M | $3.48 |
| Q3 2019 | +222,560 | Add 8.82% | 2.75 M | $4.63 |
| Q2 2019 | +367,718 | Add 17.06% | 2.52 M | $12.32 |
| Q1 2019 | +914,200 | Add 73.67% | 2.16 M | $13.29 |
| Q4 2018 | +88,082 | Add 7.64% | 1.24 M | $8.62 |
| Q3 2018 | +82,300 | Add 7.69% | 1.15 M | $7.49 |
| Q2 2018 | +118,200 | Add 12.41% | 1.07 M | $5.96 |
| Q1 2018 | +147,000 | Add 18.25% | 952,300 | $5.84 |
| Q4 2017 | +134,700 | Add 20.09% | 805,300 | $5.89 |
| Q3 2017 | +139,600 | Add 26.29% | 670,600 | $5.04 |
| Q2 2017 | +54,600 | Add 11.46% | 531,000 | $4.04 |
| Q1 2017 | +25,100 | Add 5.56% | 476,400 | $5.69 |
| Q4 2016 | +81,000 | Add 21.87% | 451,300 | $7.28 |
| Q3 2016 | +110,200 | Add 42.37% | 370,300 | $8.01 |
| Q2 2016 | +152,100 | Add 140.83% | 260,100 | $9.03 |
| Q1 2016 | -97,000 | Reduce 47.32% | 108,000 | $8.07 |
| Q4 2015 | +43,488 | Add 26.93% | 205,000 | $10.81 |
| Q3 2015 | +161,512 | New Buy | 161,512 | $8.11 |
| Q3 2014 | -49,500 | Sold Out | 0 | $0.00 |
| Q2 2014 | +49,500 | New Buy | 49,500 | $29.39 |
| Q1 2014 | -80,900 | Sold Out | 0 | $0.00 |
| Q4 2013 | -55,000 | Reduce 40.47% | 80,900 | $38.28 |
| Q3 2013 | +119,900 | Add 749.38% | 135,900 | $21.94 |
| Q2 2013 | +16,000 | Add 0.00% | 16,000 | $17.44 |
Renaissance Technologies (RenTech)'s Standard BioTools Investment FAQs
Renaissance Technologies (RenTech) first purchased Standard BioTools Inc. (LAB) in Q2 2013, acquiring 16,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Standard BioTools Inc. (LAB) for 43 quarters since Q2 2013.
Renaissance Technologies (RenTech)'s largest addition to Standard BioTools Inc. (LAB) was in Q2 2026, adding 992,058 shares worth $816,166.
According to the latest 13F filing for Q2 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 992,058 shares of Standard BioTools Inc. (LAB), valued at approximately $816,166.
As of the Q2 2026 filing, Standard BioTools Inc. (LAB) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Standard BioTools Inc. (LAB) was 3,366,000 shares, as reported at the end of Q2 2020.